cinacalcet hydrochloride 1mg, 2.5mg and 5mg granules in capsules for opening (Mimpara®)
Amgen Ltd

7 February 2020

**ADVICE**: in the absence of a submission from the holder of the marketing authorisation cinacalcet hydrochloride granules in capsules for opening (Mimpara®) is not recommended for use within NHSScotland.

**Indication under review:**

**Secondary hyperparathyroidism (HPT)**
- Treatment of secondary HPT in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.
- Treatment of secondary HPT in children aged 3 years and older with ESRD on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy

**Parathyroid carcinoma and primary HPT in adults**
- Reduction of hypercalcaemia in adult patients with:
  - parathyroid carcinoma.
  - primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated

The holder of the marketing authorisation has not made a submission to SMC regarding this product in these indications. As a result we cannot recommend its use within NHSScotland.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful consideration and evaluation of the available evidence. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

**Vice Chairman**
Scottish Medicines Consortium

Published 9 March 2020